AlphaStocks
7.5
Strong Buy

Incyte Corp (INCY)

As of Sep 20, 2026, Incyte Corp (INCY) scores 7.5/10 on AlphaStocks' five-model composite, #3 of 168 Health Care stocks. At $125, INCY trades 36% below its model fair value of $195.

Health Care / Biotechnology

S&P 500

$125.31

Above average across most dimensions. A solid candidate.

Strong Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#3out of 168 in Health Care

Is INCYTE CORP a Good Investment in 2026?

INCYTE CORP (INCY) scores 7.5 out of 10 on AlphaStocks' composite model, earning a Strong Buy rating. The Piotroski model rates INCYTE CORP as Strong (7/9). The Lynch model is the least favorable, rating it Neutral. INCYTE CORP currently trades 36% below its estimated fair value of $195. INCYTE CORP ranks #3 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E19.6ROE26.0Market Cap26B

Estimated Fair Value

$195.2136% below

Trading below estimated fair value. EPS grew 4038% year-over-year. ROE of 26% signals strong profitability. P/E of 20x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

92% above fair value

Lynch

Neutral

PEG 1.0 · Fast Grower

Greenblatt

Attractive

Earnings yield 7.4% · ROC 36%

Frequently Asked Questions

Is INCYTE CORP (INCY) a good investment?
As of Sep 20, 2026, Incyte Corp (INCY) scores 7.5/10 on AlphaStocks' five-model composite, #3 of 168 Health Care stocks. At $125, INCY trades 36% below its model fair value of $195. That score is above average across most investment dimensions.
What is INCYTE CORP's Piotroski F-Score?
INCYTE CORP's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is INCY overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $195, INCY appears undervalued. The stock currently trades 36% below its estimated fair value. Trading below estimated fair value. EPS grew 4038% year-over-year. ROE of 26% signals strong profitability. P/E of 20x is moderate for this quality level.
How does INCY compare to other Health Care stocks?
INCYTE CORP ranks #3 out of 168 stocks in the Health Care sector, placing it in the top 2% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about INCY?
AlphaStocks evaluates INCY using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 7.5/10.

Similar Stocks

ABBVHRMYHALO

Compare INCY with

ABBV vs INCYHRMY vs INCYHALO vs INCYAZN vs INCY

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer